Grifols Diagnostic Solutions Inc.

Grifols Diagnostic Solutions is a global leader in transfusion medicine diagnostics and clinical laboratory testing, serving blood banks, hospital transfusion centers, and clinical laboratories. The company manufactures and markets a comprehensive portfolio of donor screening and typing solutions, patient testing systems, and clinical diagnostic instruments. In donor testing, Grifols offers the Procleix Panther and Procleix Xpress systems for nucleic acid testing (NAT) with multiple assays including Ultrio Elite, Babesia, HEV, Parvo/HAV, Plasmodium, and arbovirus panels. For patient testing, the company provides HELIOS and HELIA automated immunoassay systems for autoimmunity testing (IFA and immunoblot), the Chorus Trio instrument for infectious disease diagnostics, and genotyping solutions. Grifols also supplies biological drug monitoring systems (Promonitor), SARS-CoV-2 serology assays, and A1AT genotyping tests. Supporting these instruments are integrated software solutions including Procleix NAT Manager, Bloodstream, and HERA middleware for laboratory workflow management. The company emphasizes laboratory efficiency, turnaround time reduction, and reliability. Grifols provides comprehensive support services including technical support, maintenance, calibration, training, and consulting through its FlexLab program. The organization maintains sophisticated cybersecurity protocols and pursues sustainability initiatives. Grifols has a longstanding history spanning over a century in diagnostic innovation and serves healthcare systems globally with regulatory clearances for US and international markets.